Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study
Abstract Background Rivaroxaban could be an attractive alternative to low molecular weight heparin for the treatment of cancer‐associated venous thromboembolism (VTE) but the safety and effectiveness remain unclear. We examined risk of recurrent VTE and major bleeding associated with rivaroxaban tre...
Saved in:
Main Authors: | Mette Søgaard, Peter Brønnum Nielsen, Flemming Skjøth, Jette Nordstrøm Kjældgaard, Torben Bjerregaard Larsen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-03-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.1997 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of drug interactions with apixaban on clinical outcomes in cancer patients with venous thromboembolism
by: Marte Svalastoga, et al.
Published: (2025-01-01) -
SECONDARY PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) WITH LOW DOSE APIXABAN OR RIVAROXABAN: RESULTS FROM A PATIENT POPULATION WITH MORE THAN 2 YEARS OF MEDIAN FOLLOW-UP
by: Alessandro Laganà, et al.
Published: (2024-02-01) -
Multimorbidity is associated with risk of incident venous thromboembolism – A nationwide proof-of-concept study
by: Jonatan Ahrén, et al.
Published: (2025-03-01) -
Biological Aging and Venous Thromboembolism: A Review of Telomeres and Beyond
by: Rafaela Vostatek, et al.
Published: (2024-12-01) -
From the right ventricle to the descending aorta: a Case Report of complex thrombotic events in a patient with nephrotic syndrome
by: Jiaojiao Chen, et al.
Published: (2025-01-01)